Sermorelin

Peptides like growth hormone secretagogues and analogues are marketed for muscle growth and recovery but lack clinical evidence for supraphysiological use.; Potential risks include cardiovascular strain, insulin resistance, dyslipidemia, and psychiatric instability.; Unregulated supply chains lead to mislabeled or contaminated products, exacerbating health dangers.; Prevalence data on recreational use, especially among younger individuals, is critically lacking.

Efficient extraction of peptidic analytes from urine was achieved for insulins, growth hormone-releasing hormones, insulin-like growth factors, synacthen, gonadorelin, and mechano growth factors.; Five internal standards were used to cover all five included peptide drug categories.; The method fulfills nearly all WADA technical document requirements for minimum required performance levels.; Proof of principle was demonstrated using authentic post-administration urine samples for insulins and gonadorelin.

GHRP-4, GHRP-6, and Sermorelin (22-29) were stable to enzyme and blood treatment.; These three peptides can serve as in-house internal standards for peptide quantification.; GHRP-6 and Sermorelin (22-29) were used to analyze a dimeric peptide in four different matrices.; A unique protein binding and enzymatic stability profile was established for each peptide.

Method detects tesamorelin, CJC-1295, sermorelin (GRF 1-29), sermorelin (3-29)-NH2, and somatorelin.; LOD of 0.2 ng/mL and LOQ of 0.6 ng/mL achieved.; Linearity established from 0.1 ng/mL to 1.2 ng/mL.; Validated per WADA criteria for selectivity, LOD, carryover, reliability, stability, and recovery.

First separation of GHRH enantiopeptides (sermorelin and CJC-1293) differing by one chiral amino acid.; PS-LVSS with 80% capillary volume injection outperformed sweeping in signal enhancement.; Adding 0.1 mM phosphoric acid with 30% methanol to sample doubled signal compared to water.; Method achieved 640-fold signal enhancement in desalted urine versus CZE without preconcentration.

Limits of detection were 5-25 pg/mL and limits of identification were 25-50 pg/mL.; Recoveries ranged from 59-115%, with similar sensitivity to immuno-affinity purification but lower costs.; Sermorelin and its metabolite degraded rapidly at temperatures >4°C and pH <7.; The method can be expanded to cover emerging peptide drugs and metabolites without specific antibodies.

Recurrent glioma patients showed highest sensitivity to sermorelin in high-throughput drug screening.; Sermorelin was effective for recurrent patients with high grade, IDH-wildtype, and 1p/19q non-codeletion status.; Sermorelin may inhibit tumor cell proliferation through cell cycle blocking and negatively regulate immune checkpoints and M0 macrophages.; Patient benefit from sermorelin was independent of postoperative adjuvant treatment.

What is Sermorelin?

**Mechanism of Action** Sermorelin (GHRH 1-29) is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH), comprising the first 29 amino acids of the native 44-amino acid peptide. It binds specifically to GHRH receptors on anterior pituitary somatotroph cells, activating the cAMP/PKA signaling pathway

How does Sermorelin work?

GHRH(1-29) analog that binds pituitary GHRH receptors to stimulate pulsatile growth hormone release.

What is the research status of Sermorelin?

Sermorelin is currently classified as approved, with 24 research references on record. This is for research purposes only and is not medical advice.

What is the half-life of Sermorelin?

The reported half-life of Sermorelin is 10-20 minutes.

What is the molecular weight of Sermorelin?

Sermorelin has a molecular weight of approximately 3357.9 g/mol (formula C149H246N44O42S).